Lineage Cell Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Lineage Cell Therapeutics generated cash of -$28,566,000, which is less than the previous year. Cash used in financing activities reached the amount of $6,423,000 last year. Net change in cash is therefore $24,056,000.
Cash Flow
| 2014 | -38.85M | -1.00M | 63.62M |
|---|---|---|---|
| 2015 | -44.54M | -7.44M | 64.77M |
| 2016 | -42.32M | -10.88M | 32.78M |
| 2017 | -30.51M | -10.22M | 55.39M |
| 2018 | -30.88M | 11.81M | 5.77M |
| 2019 | -31.94M | 16.95M | 617K |
| 2020 | -19.75M | 13.03M | 29.86M |
| 2021 | -23.56M | 9.74M | 36.93M |
| 2022 | 1.05M | -46.15M | 1.63M |
| 2023 | -28.56M | 46.44M | 6.42M |
LCTX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 11.93M | 56.27M | 33.18M | 10.09M | 24.39M | 37.68M | 22.08M | 42.22M | 29.48M | 5.49M |
Operating activities | ||||||||||
Net income | -21.48M | -26.35M | -43.27M | -20.68M | -11.82M | -46.78M | -23.28M | 18.62M | -58.13M | -43.77M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 692K | 727K | 873K | 2.03M | 3M | 3.27M | 3.29M | 4.75M | 6.33M | 8.41M |
Stock-based compensation expense | 4.64M | 4.28M | 3.51M | 2.22M | 3.58M | 0 | 3.93M | 7.95M | 11.05M | 4.45M |
| Deferred income tax benefit | 4.64M | 4.28M | 3.51M | 2.22M | 3.58M | 0 | 3.93M | 7.95M | 11.05M | 4.45M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -446K | 50.31M | -857K | 287K | 467K | 46K | -172K | -39K | -248K | -73.78K |
Inventories | 0 | 0 | -72K | -308K | 2.88M | 122K | 1.30M | -75K | -75K | -87.32K |
Accounts payable | -2.29M | -18.70M | 21.64M | 308K | -2.88M | 1.1M | 1.29M | 12K | 1.67M | -469.75K |
Cash generated by operating activities | -28.56M | 1.05M | -23.56M | -19.75M | -31.94M | -30.88M | -30.51M | -42.32M | -44.54M | -38.85M |
Investing activities | ||||||||||
Purchases Of Investments | -16.40M | -53.41M | 6.02M | 4.56M | -14.21M | -8K | -189K | -748K | -1.24M | 0 |
Investments In Property Plant And Equipment | -674K | -413K | -354K | -64K | -440K | -3.28M | -1.32M | -2.52M | -5.33M | -483.09K |
Acquisitions Net | 0 | 45.74M | 10.08M | 13.06M | 17.33M | 15.11M | -8.89M | -8.37M | 0 | 0 |
Cash generated by investing activities | 46.44M | -46.15M | 9.74M | 13.03M | 16.95M | 11.81M | -10.22M | -10.88M | -7.44M | -1.00M |
Financing activities | ||||||||||
Common Stock Issued | 6.62M | 148K | 30.86M | 5.12M | 103K | 6M | 59.67M | 30.84M | 49.10M | 44.61M |
Payments for dividends | 0 | 0 | 0 | 0 | -182K | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -37K | -17K | -54K | -27K | -110K | -241K | -888K | 0 | 0 | 0 |
Repayments of term debt | -54K | -32K | -20K | -26K | -100K | -349K | 172K | -145K | 196K | -26.21K |
Cash used in financing activities | 6.42M | 1.63M | 36.93M | 29.86M | 617K | 5.77M | 55.39M | 32.78M | 64.77M | 63.62M |
Net Change In Cash | 24.05M | -44.34M | 23.09M | 23.08M | -14.30M | -13.28M | 14.75M | -20.14M | 12.74M | 23.99M |
Cash at end of period | 35.99M | 11.93M | 56.27M | 33.18M | 10.09M | 24.39M | 36.83M | 22.08M | 42.22M | 29.48M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |